Motivational interview-based health mediator interventions increase intent to vaccinate among disadvantaged individuals.

Vaccine readiness disadvantaged populations health mediation motivational interviewing vaccine hesitancy vaccine intention

Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
08 2023
Historique:
medline: 5 10 2023
pubmed: 29 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

Coverage for recommended COVID-19 and diphtheria-tetanus-poliomyelitis (DTP) booster shots is often inadequate, especially among disadvantaged populations. To help health mediators (HMs) involved in outreach programs deal with the problems of vaccine hesitancy (VH) in these groups, we trained them in motivational interviewing (MI). We evaluated the effectiveness of this training among HMs on their MI knowledge and skills (objective 1) and among the interviewees on their vaccination readiness (VR) and intention to get vaccinated or accept a booster against COVID-19 and/or DTP (objective 2). Two MI specialists trained 16 HMs in a two-day workshop in May 2022. The validated MISI questionnaire evaluated HMs' acquisition of MI knowledge and skills (objective 1). Trained HMs offered an MI-based intervention on vaccination to people in disadvantaged neighborhoods of Marseille (France). Those who consented completed a questionnaire before and after the interview to measure VR with the 7C scale and intentions regarding vaccination/booster against COVID-19 and DTP (objective 2). The training resulted in HMs acquiring good MI skills (knowledge, application, self-confidence in using it). HMs enrolled 324 interviewees, 96% of whom completed both questionnaires. VR increased by 6%, and intentions to get vaccinated or update COVID-19 and DTP vaccination increased by 74% and 52% respectively. Nearly all interviewees were very satisfied with the interview, although 21% still had questions about vaccination. HMs assimilated MI principles well. MI use in outreach programs appears to show promise in improving vaccine confidence and intentions among disadvantaged people.

Identifiants

pubmed: 37772602
doi: 10.1080/21645515.2023.2261687
pmc: PMC10543359
doi:

Substances chimiques

Diphtheria-Tetanus Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2261687

Références

Hum Vaccin Immunother. 2022 Nov 30;18(6):2114253
pubmed: 36494997
Hum Vaccin Immunother. 2019;15(3):732-739
pubmed: 30457421
Am J Med Qual. 2022 Jul-Aug 01;37(4):348-355
pubmed: 35353474
Int J Environ Res Public Health. 2022 Dec 20;20(1):
pubmed: 36612352
BMC Public Health. 2012 Nov 01;12:940
pubmed: 23114050
Expert Rev Vaccines. 2017 Nov;16(11):1107-1118
pubmed: 28914112
Vaccine. 2011 Sep 2;29(38):6598-605
pubmed: 21763384
Vaccine. 2020 Jul 14;38(33):5131-5138
pubmed: 32409135
Vaccines (Basel). 2022 Jan 29;10(2):
pubmed: 35214670
Vaccine. 2019 May 6;37(20):2748-2756
pubmed: 30954309
BMJ Open. 2022 Sep 20;12(9):e062051
pubmed: 36127102
Euro Surveill. 2019 Sep;24(36):
pubmed: 31507265
Hum Vaccin Immunother. 2019;15(10):2446-2452
pubmed: 30829114
JMIR Res Protoc. 2022 Oct 21;11(10):e37713
pubmed: 36194870
J Community Health. 2023 Jun;48(3):430-445
pubmed: 36604393
Hum Vaccin Immunother. 2019;15(1):113-120
pubmed: 30095325
JAMA Netw Open. 2022 Jun 1;5(6):e2217875
pubmed: 35731520
Infect Control Hosp Epidemiol. 2015 Dec;36(12):1444-50
pubmed: 26383964
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
BMC Public Health. 2019 Feb 6;19(1):160
pubmed: 30727991
Int J Environ Res Public Health. 2022 Aug 12;19(16):
pubmed: 36011606
Euro Surveill. 2023 Sep;28(38):
pubmed: 37733238
J Epidemiol Glob Health. 2022 Mar;12(1):7-12
pubmed: 34978708
J Health Care Poor Underserved. 2022;33(4S):25-43
pubmed: 36533457
Prev Med Rep. 2022 Jun;27:101802
pubmed: 35493961
Contemp Clin Trials Commun. 2020 Nov 26;20:100684
pubmed: 33319119

Auteurs

Chloé Cogordan (C)

Southeastern Health Regional Observatory, ORS PACA, Marseille, France.

Lisa Fressard (L)

Southeastern Health Regional Observatory, ORS PACA, Marseille, France.

Lauriane Ramalli (L)

Santé publique France (French National Public Health Agency), Marseille, France.

Stanislas Rebaudet (S)

Hôpital Européen, Marseille, France.
UMR1252 SESSTIM, Aix-Marseille University, Inserm, IRD, ISSPAM, Marseille, France.

Philippe Malfait (P)

Santé publique France (French National Public Health Agency), Marseille, France.

Anne Dutrey-Kaiser (A)

Prospective and Cooperation Association, Marseille, France.

Yazid Attalah (Y)

SEPT Association, Marseille, France.

David Roy (D)

Centre de recherche du CHUS, Sherbrooke, QC, Canada.

Patrick Berthiaume (P)

Les formations perspective santé Inc, Québec, Canada.

Arnaud Gagneur (A)

Centre de recherche du CHUS, Sherbrooke, QC, Canada.
Department of Pediatrics, Sherbrooke University, Sherbrooke, QC, Canada.

Pierre Verger (P)

Southeastern Health Regional Observatory, ORS PACA, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH